Chinanews client, Beijing, January 24th (Reporter Zhang Ni) A few days ago, an event organized by the National Clinical Research Center for Blood System Diseases and the Institute of Hematology of Peking University was "Break thousands of new students, innovation for mission". Held in Beijing.

The reporter learned from the event that as of early 2021, the number of bone marrow transplants completed by the Peking University Institute of Blood has exceeded 10,000.

　　Leukemia, commonly known as "blood cancer", is a type of malignant disease originating from hematopoietic (lymph) stem cells.

Studies have shown that the most effective way to treat the disease is to perform hematopoietic stem cell transplantation (commonly known as bone marrow transplantation).

　　The Institute of Hematology, Peking University was the first place in China to fight leukemia.

　　In 1964, Lu Daopei, the "founder of Chinese bone marrow transplantation," completed the first hematopoietic stem cell transplantation in Asia and the fourth in the world at Peking University People's Hospital.

The Institute of Hematology, Peking University was established in 1981, and the first allogeneic hematopoietic stem cell transplantation in China was successfully carried out in the same year.

　　Since 2004, Huang Xiaojun, Director of the Institute of Hematology, Peking University, has inherited and led the team to create the first non-in vitro T haplotype-compatible hematopoietic stem cell transplantation system-the "Beijing Plan" recognized by international peers, which successfully broke through the transplant forbidden zone This solves the worldwide medical problem of the lack of donor sources. As a result, the range of donors for bone marrow transplantation has been expanded from direct blood relatives to uncles and cousins.

　　The reporter learned that the "Beijing Plan" has now covered 95% of China's and more than 50% of the world's haploidentical transplant cases, and has become the current global mainstream treatment for leukemia.

　　In 2018, the Department of Hematology, Peking University People's Hospital was approved as the National Clinical Research Center for Hematological Diseases.

For a long time, the survival rate of haploidentical transplantation patients from the Peking University Blood Research Institute is among the best in the world. The long-term survival rate of patients with hematological malignancies is 70%-80%, and that of patients with non-malignant hematological diseases is 80%-90%.

　　As the world's largest allogeneic hematopoietic stem cell transplantation center, the number of hematopoietic stem cell transplants in Peking University Institute of Blood in 2019 exceeded 1,000.

The key technology of the "Beijing Plan" was extended to 92 transplant centers across the country, as well as more than 10 overseas transplant centers in Italy, Israel, France, and South Korea.

　　After continuous exploration, by early 2021, Peking University Blood Research Institute has completed the 10,000th bone marrow transplant.

(Finish)